Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Depreciation & Amortization (CF) (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 30.37% to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Dec 2025, down 15.45% year-over-year, with the annual reading at $4.1 million for FY2025, 15.45% down from the prior year.
  • Depreciation & Amortization (CF) hit $1.0 million in Q4 2025 for Cumberland Pharmaceuticals, roughly flat from $1.0 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.7 million in Q1 2022 to a low of $511483.0 in Q4 2022.
  • Historically, Depreciation & Amortization (CF) has averaged $1.2 million across 5 years, with a median of $1.2 million in 2023.
  • Biggest five-year swings in Depreciation & Amortization (CF): crashed 52.51% in 2022 and later surged 141.12% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at $1.1 million in 2021, then plummeted by 52.51% to $511483.0 in 2022, then soared by 141.12% to $1.2 million in 2023, then increased by 21.34% to $1.5 million in 2024, then tumbled by 30.37% to $1.0 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for CPIX at $1.0 million in Q4 2025, $1.0 million in Q3 2025, and $1.0 million in Q2 2025.